096530 - Seegene, Inc.

096530 Summary

Medical Devices

Stock Price & Overview

₩31,900 +350 (+1.11%) Close · Sep 4, 2026 KST

KOSDAQ | ₩KRW | Close: ₩31,900 ≈ US$23 · Market cap ₩1.7tn (≈ $1.2bn)

096530 Financial Statements

Breakdown ₩ tn	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017	FY2016	FY2015
Total Revenue	0.47	0.41	0.37	0.85	1.37	1.13	0.12	0.10	—	0.07	0.07
Cost of Revenue	0.17	0.18	0.16	0.36	0.37	0.27	0.04	0.03	—	0.02	0.02
Gross Profit	0.30	0.24	0.21	0.50	1.00	0.86	0.08	0.07	—	0.05	0.05
Operating Income	0.03	-0.02	-0.03	0.20	0.67	0.68	0.02	0.01	—	0.01	0.01
Finance Income	0.05	0.05	0.04	0.07	0.04	0.02	0.00	0.00	—	0.00	0.00
Finance Costs	0.02	0.02	0.02	0.03	0.02	0.03	0.00	0.00	—	0.00	0.00
Pretax Income	0.06	-0.01	-0.00	0.23	0.69	0.67	0.03	0.01	—	0.01	0.01
Income Tax Expense	0.01	-0.00	-0.00	0.04	0.15	0.17	0.00	0.00	—	0.00	0.00
Net Income	0.05	-0.01	0.00	0.18	0.54	0.50	0.03	0.01	—	0.01	0.01
Total Comprehensive Income	0.06	-0.00	0.01	0.19	0.54	0.50	0.03	0.01	—	0.01	0.01

Breakdown ₩ tn	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017	FY2016	FY2015
Total Assets	1.24	1.22	1.25	1.39	1.49	1.09	0.20	0.16	0.16	0.21	0.19
Current Assets	0.80	0.76	0.78	0.90	1.05	0.78	0.14	0.12	0.11	0.16	0.15
Cash & Cash Equivalents	0.23	0.26	0.19	0.52	0.43	0.31	0.05	0.03	0.03	0.05	0.04
Inventories	0.08	0.11	0.14	0.16	0.21	0.14	0.02	0.02	0.02	0.01	0.01
Trade Receivables	0.10	0.09	0.09	0.11	0.34	0.31	0.05	0.05	0.05	0.05	0.06
Non-current Assets	0.44	0.46	0.47	0.49	0.44	0.31	0.06	0.05	0.04	0.05	0.04
Property, Plant & Equipment	0.22	0.23	0.24	0.26	0.24	0.19	0.02	0.02	0.02	0.02	0.01
Intangible Assets	0.03	0.03	0.03	0.02	0.01	0.01	0.01	0.01	0.01	0.02	0.02
Total Liabilities	0.22	0.22	0.22	0.24	0.41	0.45	0.04	0.04	0.04	0.07	0.06
Current Liabilities	0.17	0.16	0.16	0.17	0.29	0.38	0.03	0.03	0.03	0.01	0.01
Non-current Liabilities	0.05	0.06	0.06	0.07	0.12	0.07	0.01	0.01	0.01	0.05	0.05
Total Equity	1.02	0.99	1.03	1.15	1.08	0.65	0.15	0.13	0.12	0.14	0.14
Share Capital	0.03	0.03	0.03	0.03	0.03	0.01	0.01	0.01	0.01	0.01	0.01
Retained Earnings	1.09	1.08	1.12	1.16	1.03	0.56	0.07	0.04	0.03	0.05	0.05

Breakdown ₩ bn	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017	FY2016	FY2015
Cash from Operating Activities	149.3	85.4	94.9	319.0	334.0	383.2	27.1	14.0	—	16.6	-3.1
Cash from Investing Activities	-133.2	34.7	-278.3	-104.0	-102.7	-192.7	-6.9	1.0	—	-9.8	-24.3
Purchase of Property, Plant & Equipment	37.4	40.0	25.2	63.3	61.7	174.0	4.1	2.9	—	5.9	3.2
Cash from Financing Activities	-64.0	-63.7	-156.7	-144.5	-110.3	71.9	-4.2	-10.1	—	1.9	48.6
Dividends Paid	36.9	36.9	38.1	51.1	70.0	2.6	—	—	—	—	—
Net Change in Cash	-34.1	69.4	-331.0	89.2	124.0	259.0	16.5	4.8	—	8.9	21.4

Breakdown ₩ bn	2026 Q2	2026 Q1	2025 Q4	2025 Q3	2025 Q2	2025 Q1	2024 Q4	2024 Q3	2024 Q2	2024 Q1
Total Revenue	136.0	129.1	130.6	113.5	114.1	116.0	115.3	108.8	100.1	89.9
Cost of Revenue	41.2	42.4	45.8	42.4	44.8	37.3	59.1	40.8	36.6	39.1
Gross Profit	94.7	86.7	84.8	71.1	69.2	78.7	56.2	68.0	63.6	50.9
Operating Income	21.6	23.6	6.9	9.6	3.1	14.8	-6.2	5.3	-1.1	-14.4
Finance Income	12.0	19.3	16.7	9.1	8.8	11.6	21.4	1.4	12.5	13.6
Finance Costs	0.5	4.3	2.9	0.6	14.0	2.9	3.3	5.2	4.2	3.8
Pretax Income	34.5	39.3	15.2	18.5	-0.8	23.5	-36.0	1.2	28.8	-3.5
Income Tax Expense	8.6	4.6	10.2	3.9	-0.7	5.4	8.1	-0.5	4.8	-1.5
Net Income	26.0	34.7	5.0	14.6	-0.1	28.9	-44.1	1.7	24.1	-2.0
Total Comprehensive Income	29.0	40.2	10.0	19.2	-2.9	33.2	-38.6	-2.9	23.7	1.3

Breakdown ₩ tn	2026 Q2	2026 Q1	2025 Q4	2025 Q3	2025 Q2	2025 Q1	2024 Q4	2024 Q3	2024 Q2	2024 Q1
Total Assets	1.27	1.26	1.24	1.22	1.21	1.24	1.21	1.25	1.27	1.25
Current Assets	0.82	0.83	0.80	0.77	0.76	0.78	0.75	0.76	0.77	0.77
Cash & Cash Equivalents	0.27	0.26	0.23	0.22	0.27	0.25	0.26	0.21	0.23	0.19
Inventories	0.08	0.08	0.08	0.09	0.10	0.10	0.11	0.12	0.12	0.13
Trade Receivables	0.13	0.12	0.10	0.09	0.10	0.09	0.09	0.09	0.10	0.08
Non-current Assets	0.45	0.43	0.44	0.45	0.45	0.46	0.46	0.49	0.49	0.49
Property, Plant & Equipment	0.25	0.23	0.22	0.22	0.22	0.23	0.23	0.23	0.23	0.24
Intangible Assets	0.03	0.03	0.03	0.04	0.04	0.04	0.03	0.04	0.04	0.03
Total Liabilities	0.23	0.23	0.22	0.21	0.22	0.23	0.22	0.22	0.22	0.23
Current Liabilities	0.18	0.19	0.17	0.16	0.16	0.17	0.16	0.16	0.15	0.16
Non-current Liabilities	0.05	0.05	0.05	0.05	0.06	0.06	0.06	0.07	0.07	0.07
Total Equity	1.04	1.02	1.02	1.00	0.99	1.01	0.98	1.03	1.04	1.03
Share Capital	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03
Retained Earnings	1.12	1.10	1.09	1.08	1.07	1.08	1.06	1.12	1.13	1.11

Breakdown ₩ bn	2026 Q2	2026 Q1	2025 Q4	2025 Q3	2025 Q2	2025 Q1	2024 Q4	2024 Q3	2024 Q2	2024 Q1
Cash from Operating Activities	36.3	39.7	45.8	37.2	10.6	55.7	5.9	42.7	20.1	16.8
Cash from Investing Activities	6.5	3.5	-28.8	-76.8	37.7	-65.2	45.3	-36.1	36.0	-10.6
Purchase of Property, Plant & Equipment	28.9	11.4	11.4	7.3	8.7	9.9	15.1	11.2	7.3	6.4
Cash from Financing Activities	-38.1	-18.9	-17.2	-14.7	-24.8	-7.3	-16.3	-16.8	-24.2	-6.4
Dividends Paid	—	—	9.2	9.2	—	—	9.2	9.3	—	—
Net Change in Cash	8.6	32.4	5.1	-48.3	20.3	-11.2	44.8	-15.1	35.7	4.0

Consolidated (CFS), from DART. 11 fiscal years and 10 quarters. Accounts matched on IFRS account_id, not Korean labels, so the same line holds across years where the Korean wording changed. Quarterly figures are three-month values: income quarters from DART's three-month column, cash-flow quarters differenced from DART's cumulative figures, and Q4 as annual minus nine-month cumulative.

096530 Growth

FY2025 ₩bn	Latest	1-yr	3-yr CAGR	5-yr CAGR	10-yr CAGR
Revenue	474.2	+14.5%	-17.8%	-15.9%	+22.0%
Operating income	34.5	—	-44.0%	-44.8%	+14.9%
Net income	48.4	—	-35.7%	-37.4%	+21.7%
EPS	₩928	—	-35.7%	-37.4%	+21.7%
Operating cash flow	149.3	+74.9%	-22.4%	-17.2%	—
Shareholders' equity	1,015.8	+2.3%	-4.1%	+9.5%	+22.3%

Compound annual growth from the DART annual statements on this page. n/m where either end of the period is a loss or missing. EPS uses today's share count for every year.

096530 Profitability

Ratio	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020
Gross margin	64.1%	57.6%	57.7%	58.1%	73.3%	76.2%
Operating margin	7.3%	-4.0%	-8.2%	23.0%	48.6%	60.1%
Net margin	10.2%	-2.1%	0.2%	21.4%	39.2%	44.7%
Return on equity	4.8%	-0.9%	0.1%	16.3%	62.1%	125.9%
Return on assets	4.0%	-0.7%	0.1%	12.7%	41.6%	78.0%
Operating cash flow / revenue	31.5%	20.6%	25.8%	37.4%	24.4%	34.1%
Capex / revenue	7.9%	9.7%	6.8%	7.4%	4.5%	15.5%

Margins divide by revenue for the same year. Return on equity and assets divide net income by the average of that year's and the prior year's balance, as DART reports them (consolidated, including minority interests).

Similar to 096530

Symbol	Last Price
214450Pharma Research Co., Ltd.	₩386,500 +1.4%
214150Classys, Inc.	₩31,800 +0.3%
491000Livs Med, Inc.	₩34,500 +3.6%
041830In Body Co., Ltd.	₩61,100 +2.5%
445680Curiox Biosystems Co., Ltd.	₩47,650 -1.5%
458870Seers Co., Ltd.	₩21,350 +3.1%
137310SD Biosensor	₩6,160 -0.3%
377740Bio Note, Inc.	₩4,790 -0.2%
340570T & L Co., Ltd.	₩29,650 +1.2%
099190i-SENS, Inc.	₩16,470 +0.0%

Compare all 13 in Medical Devices

What a US investor should know

Trading hours09:00–15:30 KST — 20:00–02:30 US Eastern the night before.
Daily limitKorean stocks can move at most ±30% in a session before trading halts.
Getting exposureKRX shares are not directly tradable in most US brokerage accounts. The usual routes are Korea ETFs or an international account.
ReportingKorean issuers file to DART, not the SEC. Half-year and quarterly reports land about 45 days after period end.